Aegle Therapeutics
Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles ("EVs") from allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”).
All edits
May 1, 2018
On May 1, 2018 Aegle Therapeutics completed their seed funding round with and undisclosed amount of funding from Ocean Azul Partners.
On May 1, 2018 Aegle Therapeutics completed their seed funding round with and undisclosed amount of funding from Ocean Azul Partners.
Aegle Therapeutics has proprietary technology for extracellular vesicle isolation. The U.S. Food and Drug Administration (FDA) cleared the company's first Investigational New Drug (IND) application to begin clinical trials in burn patients in 2018.The Phase 1/2a study includes severe second degree burn patients and will evaluate the safety of extracellular vesicle therapy and is an open label dose escalation protocol in patients at several sites in the United States.
Find more companies like Aegle Therapeutics
